Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income attributable to Lineage Cell Therapeutics, Inc.	$ (14,921)	$ 9,278
Net loss allocable to noncontrolling interest	(37)	(34)
Adjustments to reconcile net (loss) income attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Unrealized gain on equity method investment in OncoCyte at fair value		(16,288)
Unrealized gain on equity method investment in Asterias at fair value		(6,744)
Gain on sale of marketable securities	(3,728)
Unrealized loss (gain) on marketable equity securities	5,484	(1,324)
Deferred income tax benefit		(5,632)
Depreciation expense, including amortization of leasehold improvements	423	513
Amortization of right-of-use asset	18	27
Amortization of intangible assets	831	992
Stock-based compensation	1,232	2,202
Change in unrealized gain on warrant liability	(29)	(271)
Write-off of security deposit	150
Foreign currency remeasurement and other (gain) loss	236	(1,461)
Changes in operating assets and liabilities:
Accounts and grants receivable, net	125	(863)
Accrued interest receivable	(756)	(756)
Receivables from OncoCyte and AgeX, net of payables		2,185
Prepaid expenses and other current assets	1,442	(1)
Accounts payable and accrued liabilities	214	(804)
Deferred revenue and other liabilities	51
Net cash used in operating activities	(9,265)	(18,981)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of OncoCyte common shares	10,941
Proceeds from the sale of AgeX common shares	985
Cash and cash equivalents acquired in the Asterias Merger		3,117
Purchase of equipment and other assets	(16)	(364)
Security deposit paid and other	48	(1)
Net cash provided by investing activities	11,958	2,752
CASH FLOWS FROM FINANCING ACTIVITIES:
Common shares received and retired for employee taxes paid	(13)	(77)
Reimbursement from landlord on tenant improvements		744
Repayment of financing lease liabilities	(17)	(14)
Proceeds from Paycheck Protection Program (“PPP”) Loan (Note 8)	523
Proceeds from sale of subsidiary warrants		(40)
Repayment of principal portion of promissory notes		(70)
Net cash provided by financing activities	493	543
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(38)	83
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	3,148	(15,603)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period	10,096	24,399
At end of the period	$ 13,244	$ 8,796